Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

acebo consistently across all five endpoints studied, including both of the endpoints accepted by the FDA to register drugs for mild to moderate Alzheimer's disease. And second, Dimebon was well tolerated in this study, with less than three percent incidence of the gastrointestinal side effects that sometimes limit utilization of approved cholinesterase inhibitor drugs. Based on these data, I look forward to participating in the planned Phase 3 trials of this promising drug candidate."

The study of 183 patients was conducted at multiple sites in Russia. Patients received oral Dimebon, 20 mg three times a day (60 mg/day), or placebo. The primary efficacy endpoint was the ADAS-cog and the secondary efficacy endpoints were the CIBIC-plus, the MMSE, the ADCS-ADL and the NPI. Medivation is presently completing a 12-month extension of this trial and expects to report top-line data in the second quarter of 2007. Medivation also expects to enter global Phase 3 studies of Dimebon in Alzheimer's disease in 2008 and, assuming positive data, to submit marketing applications in the U.S. and Europe in 2010 for this indication.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Abo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/17/2009)... to Fix the Bill ,, WASHINGTON, Dec. ... Coalition for a Competitive Pharmaceutical Market (CCPM) will ... and in select states charging that, during this ... gift of all to brand pharmaceutical companies" by ... ads urge the President to tell Congress to ...
(Date:12/17/2009)... PALM CITY, Fla., Dec, 17 Connectyx ... today that it has formed a distribution partnership ... Order distributor of Diabetic Supplies, Respiratory Supplies and ... the VED Erectile Dysfunction System. ,, Terms of ... Ronn Schuman stated that, "This partnership adds to ...
(Date:12/17/2009)... Dec. 17 Frost & Sullivan ... American Healthcare Innovation Award in molecular diagnostics ... its commitment to providing innovative technologies for ... its incorporation in 2004, IntelligentMDx has introduced ... to make tests that are clinically impactful, ...
Breaking Medicine Technology:Coalition for a Competitive Pharmaceutical Market Runs Ads Stating Congress Is Giving 'Greatest Holiday Gift of All to Brand Pharmaceutical Companies' 2Coalition for a Competitive Pharmaceutical Market Runs Ads Stating Congress Is Giving 'Greatest Holiday Gift of All to Brand Pharmaceutical Companies' 3Connectyx Announces Distribution Partnership with United States Medical Supply 2Connectyx Announces Distribution Partnership with United States Medical Supply 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 1Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 2Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 3Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 53942 1Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 53942 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 1FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 2FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 3FDA Approves New 3000 IU Vial Size for Kogenate 28R 29 FS antihemophilic factor 28recombinant 29 53939 4
(Date:12/17/2009)... leading high-tech,healthcare group, Golden Meditech Company Limited ("Golden ... to announce today that the Group,s,associate company FunTalk ... Holdings Limited, made its debut on the NASDAQ ... offering. The shares of FunTalk started,trading on December ... As of today, Golden Meditech holds ...
(Date:12/17/2009)... from a recent Thomson Reuters study show that Chinese ... in 1998 to nearly 112,000 in 2008. , ... of the biomedical literature, has evaluated more than 530 ... only 27 Chinese-authored papers were selected in 2004, this ... to be even higher in 2009. , Jane Hunter, ...
(Date:12/17/2009)... hospital clients Rutherford Hospital Inc. (Rutherfordton, N.C.), a management ... management client since 1992, were recently recognized as top-ranked ... ... Brentwood, Tenn. (PRWEB) ... Rutherford Hospital Inc. (Rutherfordton, N.C.), a management client since ...
(Date:12/17/2009)... Studies Important ,for the R&D Informatics Industry, , ... ... Cambridge Healthtech Institute is pleased to announce the participation of ... R&D Informatics Systems conference to be held on February 3-5, ... CA. This meeting has been integrated in the Informatics Channel ...
(Date:12/17/2009)... -- Motionsoft, Inc. announced today that it has ... Data Security Standards (DSS) certification, making it one ... the health and wellness space that has been ... the result of a collaborative effort formed by ... MasterCard Worldwide, American Express, Discover Financial Services and ...
Breaking Medicine News(10 mins):Health News:Golden Meditech's Associate Company Debuted on NASDAQ 2Health News:China rapidly catching up in research impact 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3Health News:Motionsoft Completes PCI Compliance Certification 2
... and Washington, D.C., WASHINGTON, Oct. 13 ... Coping With Deployments: Psychological First,Aid for Military Families, ... is open to military family members of active ... veterans and their families. Presently,the course is offered ...
... among Physicians, MOUNTAIN VIEW, Calif., Oct. 13 ... IT market, Frost & Sullivan recognizes,Infor-Med, Inc. with ... for,Technology Innovation for its novel Praxis(R) Electronic Medical ... Exchanger., The Praxis(R) EMR system employs a ...
... Energy Enhancing Supplement, BOCA RATON, Fla., Oct. 13 ... Go to its line of,top quality supplements., Glyc,n ... Glycine,Propionyl-L-Carnitine (GPLC) supplement, and the effects that it has ... athletes and trainers,around the globe., In clinical trials, ...
... Inc., presented,yesterday the anatomic effects of the ... lesions in an analysis at the,American Society ... The,12-month data presented by David Brown, MD, ... anatomic improvements on both,angiography and ocular coherence ...
... of www.AtlantaJobs.com . AtlantaJobs.com is the newest online job ... Atlanta area. , ... Atlanta, GA (PRWEB) October 13, ... the official launch of AtlantaJobs.com is the newest online ...
... 13, 2008 Five neonatology fellows have been ... in the area of follow-up care of the ... The grants, which underscore MedImmune,s commitment to expanding ... institution a $35,000 grant, totaling $175,000 in research ...
Other Medicine News:Health News:American Red Cross Offering Free Class to Help Military Families Cope With the Stress of Deployments 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: